



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

processor and the second secon	**************************************		The same of the sa
APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
<u> </u>	<u> </u>	<u>}</u>	

09/522,342

03/09/2000

Timothy A. Stewart

A-68670/RMS/DAV

Flehr Hohbach Test Albritton & Herbert LLP Suite 3400 Four Embarcadero Center San Francisco, CA 94111-4187



Date Mailed: 05/18/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- · The statutory basic filing fee is missing. Applicant must submit \$ 690 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$4796.
 - \$2664 for 148 total claims over 20.
 - \$1872 for 24 independent claims over 3.
 - \$260 for multiple dependent claim surcharge.
- The oath or declaration is missing.

A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the 2006 BALEXANDOMA Application Number and Filing Date, is required.

- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$20 for a non-small entity, must be submitted with the missing items identified in this letter.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c)
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:

■ For Rules Interpretation, call (703) 308-1123	File A - 62	2670 Att	17AU
■ For CRF Submission Help, call (703) 308-4212	T	71,81	ે છે.
Patentln Software Program Support	Due Date	1,0	1×0 5 6
■ For Technical Assistance call (703) 287-0200		· .	55 <u>S</u> T

- To Purchase Patentln Software, call (703) 306-2600 Type Missing Parts

Tuly 18, 200 - Missing Parts



A copy of this notice <u>MUST</u> be returned with the reply.


1 clacks

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

AUG 2 1 2000 U



Sector 1

Patent Docket P1219R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Stewart et al.

Serial No.: 09/522,342

Filed: March 9, 2000

For: Fibroblast Growth Factor-19 (FGF-

19) Nucleic Acids and Polypeptides

and Methods of Use for the

Treatment of Obesity

Group Art Unit: Unknown

Examiner: Unknown

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

August 18, 2000

Teri Renshaw

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Box: MISSING PARTS


Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

This is responsive to the Notice to File Missing Parts dated May 18, 2000. Transmitted herewith are the following documents:

- 1. Declaration duly executed;
- 2. Copy of Notice to File Missing Parts of Application (PTO-1533);
- 3. Notice of Change of Correspondence Address;
- 4. Preliminary Amendment;
- 5. Amendment Transmittal;
- 6. Petition for one Month Extension of Time and requisite fee of \$110;
- 7. Filing fee and additional claim fees in the amount of \$3760.00, <u>including</u> the surcharge of \$130 for responding to the Notice to File Missing Parts of Application to be charged to Deposit Account No. 07-0630.



The Commissioner is hereby authorized any fees associated with this communication or credit any overpayment to Deposit Account No. 07-0630. <u>A duplicate of this sheet is enclosed.</u>

Respectfully submitted,

GENENTECH, INC.

Date: August 18, 2000

Mark T. Kresnak Reg. No. 42,767

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-4461 Fax: (650) 952-9881 AIIR 2 1 2000

Patent Docket P1219P1

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of

Timothy A. Stewart et al.

Serial No.: 09/522,342

Filed: March 9, 2000

For: Fibroblast Growth Factor-19 (FGF-

19) Nucleic Acids and Polypeptides

and Methods of use for the

Treatment of Obesity

Group Art Unit: Unknown

Examiner: Unknown

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents,

Washington, D.C. 20231 on

August/18, 2000

Teri Renshaw

AMENDMENT TRANSMITTAL

BOX: MISSING PARTS

Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	75	-	20	55	18	\$990.00
Independent	28	-	3	25	78	\$1,950.00
	_0_Multiple dep	endent	claim(s), if any		260	\$0.00
Total Fee Calculation						\$2,940.00

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3760.00 (which includes the filing fee of \$690.00 as well as the \$130.00 surcharge for responding to the Notice to Filing Missing Parts of Application.). A duplicate copy of this transmittal is enclosed.

X Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

Bv

GENENTECH, ING

Reg. No. 42,767

Date: August 18, 2000

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-4461 Fax: (650) 952-9881